Denosumab: a novel antiresorptive drug for osteoporosis

Cleve Clin J Med. 2015 Feb;82(2):105-14. doi: 10.3949/ccjm.82a.13173.

Abstract

Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Absorptiometry, Photon
  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bone Density / drug effects
  • Bone Density Conservation Agents / therapeutic use
  • Denosumab
  • Female
  • Humans
  • Lumbar Vertebrae / injuries*
  • Osteoporosis / complications
  • Osteoporosis / diagnostic imaging
  • Osteoporosis / drug therapy*
  • Osteoporotic Fractures / diagnostic imaging
  • Osteoporotic Fractures / drug therapy*
  • Osteoporotic Fractures / etiology
  • RANK Ligand / antagonists & inhibitors
  • Spinal Fractures / drug therapy
  • Spinal Fractures / etiology*
  • Thoracic Vertebrae / injuries*

Substances

  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents
  • RANK Ligand
  • Denosumab